<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01021644</url>
  </required_header>
  <id_info>
    <org_study_id>IA0172</org_study_id>
    <secondary_id>1R01AG031517-01A209</secondary_id>
    <secondary_id>1R01AG031517-01</secondary_id>
    <nct_id>NCT01021644</nct_id>
  </id_info>
  <brief_title>Genes, Exercise, Memory and Neurodegeneration</brief_title>
  <official_title>Effects of Standardized Aerobic Exercise-Training on Neurocognitive and Neurodegeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Howard University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Howard University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this pilot study is to determine whether African Americans with mild
      Alzheimer's disease (AD) can be enrolled and retained in a 6-month aerobic exercise-training
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine the effects of aerobic exercise-training on neurocognitive function,
      and on cerebral glucose homeostasis. It is yet to be determined whether African Americans
      with mild AD can be recruited into such a study, nor has the relationship of fitness
      adaptation to neurocognitive function been systematically examined in this population. In
      addition to the goal of assessing the intervention effects, the study will evaluate the
      differential relationships of APOE to aerobic fitness-induced changes in neurocognition. The
      long-term goal is to explore the mechanism by which fitness adaptation exerts an effect on
      neurocognition, notably, low levels of high-density lipoprotein cholesterol (HDL-C), elevated
      inflammation (C-reactive protein (CRP) and interleukins (IL-1A)), deranged glucose
      homeostasis, hypertension and endothelia dysfunction are precursors of arteriolosclerosis,
      decreased cerebral perfusion and oxygen deprivation, all of which may increase AD risk.
      Because many of these putative AD risk factors are susceptible to lifestyle alterations, the
      study will also assess their roles in aerobic fitness-related improvements in cognitive
      function and reduction in AD risk.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AD Assessment Scale-Cognitive (ADAS-COG)</measure>
    <time_frame>baseline, 3 and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental State Exam (MMSE)</measure>
    <time_frame>baseline, 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDR (Clinical Dementia Rating) Scale</measure>
    <time_frame>baseline, 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Logical Memory Test (Delayed Paragraph Recall)</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visuospatial and Visuographic: Clock Drawing Test</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American National Adult Reading Test (ANART)</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric Inventory Q (NPIQ)</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Depression Scale</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living (ADCS-ADL)</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET imaging to measure cerebral glucose homeostasis/metabolism</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>aerobic exercise-training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>stretch exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>aerobic exercise-training</intervention_name>
    <description>3 times per week for 6 months</description>
    <arm_group_label>aerobic exercise-training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>stretch exercise</intervention_name>
    <description>3 times per week for 6 months</description>
    <arm_group_label>stretch exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 60 years

          -  Ability to exercise vigorously without harm

          -  Mild AD

          -  Study partner

          -  In good general health

          -  Willing to exercise for 6 months

          -  Body Mass Index (BMI) less than 37

          -  Women participants must be postmenopausal for at least 2 years, and maintain current
             hormone replacement therapy status and allowed medication usage for the duration of
             the study

        Exclusion Criteria:

          -  MMSE score below 20

          -  TG (Triglyceride) greater than 400 mg/dl

          -  LDL-C levels greater than 95% or HDL-C levels less than 10% of age and sex-adjusted
             norms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas O. Obisesan, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Howard University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Howard University General Clinical Research Center (GCRC)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Exercise Physiology Laboratory</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lautenschlager NT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J, Greenop KR, Almeida OP. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008 Sep 3;300(9):1027-37. doi: 10.1001/jama.300.9.1027. Erratum in: JAMA. 2009 Jan 21;301(3):276.</citation>
    <PMID>18768414</PMID>
  </reference>
  <reference>
    <citation>Barnes LL, Wilson RS, Li Y, Gilley DW, Bennett DA, Evans DA. Change in cognitive function in Alzheimer's disease in African-American and white persons. Neuroepidemiology. 2006;26(1):16-22. Epub 2005 Oct 25.</citation>
    <PMID>16254449</PMID>
  </reference>
  <reference>
    <citation>Wilkins CH, Grant EA, Schmitt SE, McKeel DW, Morris JC. The neuropathology of Alzheimer disease in African American and white individuals. Arch Neurol. 2006 Jan;63(1):87-90.</citation>
    <PMID>16401740</PMID>
  </reference>
  <reference>
    <citation>Larson EB, Wang L, Bowen JD, McCormick WC, Teri L, Crane P, Kukull W. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med. 2006 Jan 17;144(2):73-81.</citation>
    <PMID>16418406</PMID>
  </reference>
  <reference>
    <citation>Kramer AF, Erickson KI, Colcombe SJ. Exercise, cognition, and the aging brain. J Appl Physiol (1985). 2006 Oct;101(4):1237-42. Epub 2006 Jun 15. Review.</citation>
    <PMID>16778001</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2009</study_first_submitted>
  <study_first_submitted_qc>November 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2009</study_first_posted>
  <last_update_submitted>February 13, 2014</last_update_submitted>
  <last_update_submitted_qc>February 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Howard University</investigator_affiliation>
    <investigator_full_name>Thomas Obisesan</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>APOE</keyword>
  <keyword>Apolipoprotein E</keyword>
  <keyword>Cognition Disorders</keyword>
  <keyword>Neurocognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Nerve Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

